174 related articles for article (PubMed ID: 15570205)
1. Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement.
Bogoevski D; Yekebas EF; Schurr P; Kaifi JT; Kutup A; Erbersdobler A; Pantel K; Izbicki JR
Ann Surg; 2004 Dec; 240(6):993-1000; discussion 1000-1. PubMed ID: 15570205
[TBL] [Abstract][Full Text] [Related]
2. Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy.
Bogoevski D; Chayeb H; Cataldegirmen G; Schurr PG; Kaifi JT; Mann O; Yekebas EF; Izbicki JR
J Gastrointest Surg; 2008 Nov; 12(11):1830-7; discussion 1837-8. PubMed ID: 18791769
[TBL] [Abstract][Full Text] [Related]
3. Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy.
Yekebas EF; Bogoevski D; Bubenheim M; Link BC; Kaifi JT; Wachowiak R; Mann O; Kutup A; Cataldegirmen G; Wolfram L; Erbersdobler A; Klein C; Pantel K; Izbicki JR
World J Gastroenterol; 2006 Oct; 12(40):6515-21. PubMed ID: 17072983
[TBL] [Abstract][Full Text] [Related]
4. Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance.
Hosch SB; Knoefel WT; Metz S; Stoecklein N; Niendorf A; Broelsch CE; Izbicki JR
Pancreas; 1997 Aug; 15(2):154-9. PubMed ID: 9260200
[TBL] [Abstract][Full Text] [Related]
5. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
[TBL] [Abstract][Full Text] [Related]
6. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease.
Pai RK; Beck AH; Mitchem J; Linehan DC; Chang DT; Norton JA; Pai RK
Am J Surg Pathol; 2011 Feb; 35(2):228-34. PubMed ID: 21263243
[TBL] [Abstract][Full Text] [Related]
7. Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma.
Bhatti I; Peacock O; Awan AK; Semeraro D; Larvin M; Hall RI
World J Surg; 2010 Apr; 34(4):768-75. PubMed ID: 20052471
[TBL] [Abstract][Full Text] [Related]
8. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
[TBL] [Abstract][Full Text] [Related]
9. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?
Konstantinidis IT; Deshpande V; Zheng H; Wargo JA; Fernandez-del Castillo C; Thayer SP; Androutsopoulos V; Lauwers GY; Warshaw AL; Ferrone CR
J Gastrointest Surg; 2010 Feb; 14(2):261-7. PubMed ID: 19937477
[TBL] [Abstract][Full Text] [Related]
10. Occult tumor cells in lymph nodes as a predictor for tumor relapse in pancreatic adenocarcinoma.
Scheunemann P; Stoecklein NH; Rehders A; Bidde M; Metz S; Peiper M; Eisenberger CF; Schulte Am Esch J; Knoefel WT; Hosch SB
Langenbecks Arch Surg; 2008 May; 393(3):359-65. PubMed ID: 17704938
[TBL] [Abstract][Full Text] [Related]
11. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.
John BJ; Naik P; Ironside A; Davidson BR; Fusai G; Gillmore R; Watkins J; Rahman SH
HPB (Oxford); 2013 Sep; 15(9):674-80. PubMed ID: 23458477
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma.
Malleo G; Maggino L; Nobile S; Casciani F; Cacciatori N; Paiella S; Luchini C; Rusev B; Capelli P; Marchegiani G; Bassi C; Salvia R
Eur J Surg Oncol; 2020 Sep; 46(9):1734-1741. PubMed ID: 32327367
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study.
Zheng ZJ; Wang MJ; Tan CL; Chen YH; Ping J; Liu XB
Medicine (Baltimore); 2020 Feb; 99(8):e19327. PubMed ID: 32080152
[TBL] [Abstract][Full Text] [Related]
14. [Significance of occult lymphatic tumor spread in pancreatic cancer].
Milsmann C; Füzesi L; Werner C; Becker H; Horstmann O
Chirurg; 2005 Nov; 76(11):1064-72. PubMed ID: 15971035
[TBL] [Abstract][Full Text] [Related]
15. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival.
Yu XZ; Guo ZY; Di Y; Yang F; Ouyang Q; Fu DL; Jin C
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):104-109. PubMed ID: 28119265
[TBL] [Abstract][Full Text] [Related]
16. Morphological and immunohistochemical characterization of isolated tumor cells by p53 status in gastrointestinal tumors.
Milsmann C; Füzesi L; Heinmöller E; Krause P; Werner C; Becker H; Horstmann O
Langenbecks Arch Surg; 2008 Jan; 393(1):49-58. PubMed ID: 17876601
[TBL] [Abstract][Full Text] [Related]
17. Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction.
Schurr PG; Yekebas EF; Kaifi JT; Lasch S; Strate T; Kutup A; Cataldegirmen G; Bubenheim M; Pantel K; Izbicki JR
J Surg Oncol; 2006 Sep; 94(4):307-15. PubMed ID: 16917878
[TBL] [Abstract][Full Text] [Related]
18. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
19. [Value of cytokeratin and Ca 19-9 antigen in immunohistological detection of disseminated tumor cells in lymph nodes in pancreas carcinoma].
Ridwelski K; Meyer F; Fahlke J; Kasper U; Roessner A; Lippert H
Chirurg; 2001 Aug; 72(8):920-6. PubMed ID: 11554137
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer.
Passlick B; Izbicki JR; Kubuschok B; Nathrath W; Thetter O; Pichlmeier U; Schweiberer L; Riethmüller G; Pantel K
J Clin Oncol; 1994 Sep; 12(9):1827-32. PubMed ID: 8083707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
